Business
Unverified
Gathered automatically from the outlets below; our newsroom hasn't checked it yet.
Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
